Burling Wealth Partners LLC bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 25,822 shares of the company’s stock, valued at approximately $4,532,000.
A number of other institutional investors have also made changes to their positions in the business. Mascoma Wealth Management LLC acquired a new position in AstraZeneca in the 4th quarter valued at $46,000. Elyxium Wealth LLC acquired a new position in AstraZeneca in the 4th quarter valued at $102,000. Redmont Wealth Advisors LLC acquired a new position in AstraZeneca in the 4th quarter valued at $122,000. Valley Wealth Managers Inc. acquired a new position in AstraZeneca in the 4th quarter valued at $144,000. Finally, Saranac Partners Ltd acquired a new position in AstraZeneca in the 3rd quarter valued at $876,000. 40.87% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Stock Performance
OTCMKTS:AZNCF opened at $187.10 on Thursday. The stock has a fifty day moving average price of $187.10 and a 200-day moving average price of $184.32. AstraZeneca PLC has a fifty-two week low of $122.26 and a fifty-two week high of $195.00.
About AstraZeneca
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Read More
- Five stocks we like better than AstraZeneca
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
